The addition of avibactam to ceftazidime protects ceftazidime from breakdown by certain beta-lactamases
are clinically important cephalosporinases, confer resistance to cephalothin, cefazolin, cefoxitin, most penicillins and [beta]-lactamase-[beta]-lactamase inhibitor combinations.
Detection of plasmid-mediated AmpC beta-lactamase
genes in clinical isolates by using multiplex PCR.
Detection of extended-spectrum beta-lactamases
among Enterobacteriaceae by use of semiautomated microbiology systems and manual detection procedures.
About one-tenth of isolates of Gram-negative pathogens seem to produce extended-spectrum beta-lactamases
Molecular epidemiology of an SHV-5 extended spectrum beta-lactamase
in Enterobacteriaceae isolated from infants in a neonatal intensive care unit.
NXL104, Novexel's broad spectrum non-beta-lactam class A and C beta-lactamase
inhibitor which, in combination with the cephalosporin antibiotic ceftazidime, is currently in two Phase II trials for complicated urinary tract infections (cUTIs) and complicated intra abdominal infections(cIAIs).
Version 2000: the new beta-lactamases
of Gram-negative bacteria at the dawn of the new millennium.
No beta-lactam drug or beta-lactamase
inhibitor can resist all of these enzymes.
Bacteria, however, quickly develop beta-lactamases
that don't bind those substances.
There is a growing need for antibiotics that target pathogens that express beta-lactamases
, including extended-spectrum beta-lactamases
(ESBLs), Klebsiella pneumoniae carbapenemases (KPCs), and metallo-beta-lactamases
Diversity of extended-spectrum beta-lactamases
and class C beta-lactamases
among cloacal Escherichia coli isolates in Belgian broiler farms.
In recent years increased incidence of Enterobacteriaceae possessing extended-spectrum beta-lactamases
(ESBLs) and AmpC enzymes have occurred due to wide spread use of broad-spectrum cephalosporins.
Occurrence and detection of AmpC beta-lactamases
among Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis isolates at a veterans medical center.
NXL104 has the ability to inhibit the activity of a broader range of clinically important beta-lactamases
than currently marketed beta-lactam inhibitors and we believe that this combination product could provide an important new treatment option in the hospital.